News

Enlarge image

ResearchUK

Robotic Ribosome

11.01.2013 - Researches have constructed the first molecular machine that can produce peptides of defined sequences in milligram quantities.

The group of Bartosz Lewandowski from University of Manchester have taken another step toward the creation of a synthetic machine that performs the duties of a ribosome, which builds proteins in living organisms by joining amino acids together. As reported in Science, they have designed an artificial small-molecule machine that travels along a molecular strand, picking up amino acids that block its path, to synthesise a peptide in a sequence-specific manner.

The chemical structure is based on a rotaxane, a molecular ring threaded onto a molecular axle. The ring carries a thiolate group that iteratively removes amino acids in order from the strand and transfers them to a peptide-elongation site through native chemical ligation. The synthesis was demonstrated with ~1018 molecular machines acting in parallel; this process generated milligram quantities of a peptide with a single sequence confirmed by tandem mass spectrometry.

The study demonstrates that, in principle, small artificial molecular machines can be designed to perform such tasks autonomously. However, their machine lacked performance. In the current lab setting it only joined 3 amino acids together.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/robotic-ribosome.html

R&DUKIreland

12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.10 SEK20.00%
  • KARO BIO (S)29.30 SEK19.59%
  • PLETHORA (UK)2.75 GBP4.96%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • PAION (D)1.08 EUR-13.60%

TOP

  • VERONA PHARMA (UK)3.40 GBP30.8%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.28 GBP12.0%

FLOP

  • PAION (D)1.08 EUR-56.3%
  • BIONOR PHARMA (N)0.79 NOK-51.8%
  • PROTHENA PLC (IE)30.12 USD-41.6%

TOP

  • KARO BIO (S)29.30 SEK3755.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)6.45 EUR224.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-86.1%
  • BIOTEST (D)13.81 EUR-85.2%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 11.02.2016